| Tchem | Acetyl-CoA carboxylase 2 |
Acetyl-CoA carboxylase (ACC) is a complex multifunctional enzyme system. ACC is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis. ACC-beta is thought to control fatty acid oxidation by means of the ability of malonyl-CoA to inhibit carnitine-palmitoyl-CoA transferase I, the rate-limiting step in fatty acid uptake and oxidation by mitochondria. ACC-beta may be involved in the regulation of fatty acid oxidation, rather than fatty acid biosynthesis. There is evidence for the presence of two ACC-beta isoforms. [provided by RefSeq, Jul 2008]
Comments
Property Summary
| NCBI Gene PubMed Count | 50 |
| Grant Count | 60 |
| R01 Count | 39 |
| Funding | $8,516,894.21 |
| PubMed Score | 166.49 |
| PubTator Score | 86.21 |
| Disease | log2 FC | p |
|---|---|---|
| malignant mesothelioma | -2.400 | 0.000 |
| psoriasis | -2.000 | 0.000 |
| osteosarcoma | -4.789 | 0.000 |
| group 4 medulloblastoma | -1.700 | 0.000 |
| medulloblastoma, large-cell | -2.000 | 0.000 |
| pancreatic ductal adenocarcinoma liver m... | -1.775 | 0.016 |
| non-small cell lung cancer | -2.152 | 0.000 |
| colon cancer | -2.000 | 0.000 |
| lung cancer | -4.900 | 0.000 |
| pancreatic cancer | -1.300 | 0.001 |
| Breast cancer | -2.900 | 0.024 |
| pediatric high grade glioma | -1.100 | 0.002 |
| pilocytic astrocytoma | -1.200 | 0.001 |
| primary Sjogren syndrome | -1.500 | 0.022 |
| lung adenocarcinoma | -1.550 | 0.000 |
| breast carcinoma | -2.100 | 0.000 |
| ductal carcinoma in situ | -3.900 | 0.000 |
| invasive ductal carcinoma | -5.000 | 0.000 |
| ovarian cancer | -2.500 | 0.000 |
| dermatomyositis | 1.100 | 0.007 |
CHEMBL1818188
pIC50 6.00
CHEMBL396419
pIC50 6.00
CHEMBL3686652
pIC50 6.00
CHEMBL3686663
pIC50 6.00
CHEMBL3686166
pIC50 6.00
CHEMBL3698559
pIC50 6.00
CHEMBL3686171
pIC50 6.00
CHEMBL3695044
pIC50 6.00
CHEMBL3694934
pIC50 6.00
CHEMBL3680327
pIC50 6.00
CHEMBL3686636
pIC50 6.00
CHEMBL3695041
pIC50 6.00
CHEMBL3694916
pIC50 6.00
CHEMBL1910402
pIC50 6.00
CHEMBL3658197
pIC50 6.00
CHEMBL3662382
pIC50 6.00
CHEMBL3694960
pIC50 6.00
CHEMBL3690652
pIC50 6.00
CHEMBL3690684
pIC50 6.00
CHEMBL3659836
pIC50 6.00
| PMID | Text |
|---|---|
| 26362536 | HIV-1 Gag interacts with ACACB as demonstrated by proximity dependent biotinylation proteomics |
| 26030797 | A significant association exists of ACACB gene polymorphism and diabetic nephropathy among Caucasian patients with diabetes. |
| 26022126 | The knockdown of ACC2 reduced palmitic acid -induced autophagy and thus protects the cells from palmitic acid - induced lipotoxicity with attenuated lipid accumulation and rescued cell viability. |
| 25262148 | Our meta-analysis supports that the apolipoprotein E epsilon2 allele and acetyl-CoA carboxylase beta rs2268388 C>T might act as promotion factors of nephropathy in type 2 diabetes. |
| 23460794 | These data support a role for ACACB in obesity and potential roles for altered lipid metabolism in susceptibility to diabetic nephropathy. |
| 23156397 | Its involvement in the development of diabetic nephropathy is explained by the promotion of the so-called micro-inflammation associated with the diabetic state. |
| 23081748 | TT genotypes of ACACB gene (rs2268388) and CC genotype of AGTR1 gene (rs5186) confers the risk of diabetic nephropathy in Asian Indian patients with T2DM. |
| 21953464 | Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion. |
| 21908218 | In conclusion, common polymorphisms of ACACB gene are associated with obesity and, independently, with type 2 diabetes in postmenopausal women |
| 21887335 | Common variants within the ACACB locus appear to regulate adipose gene expression |
| More... |
MVLLLCLSCLIFSCLTFSWLKIWGKMTDSKPITKSKSEANLIPSQEPFPASDNSGETPQRNGEGHTLPKT 1 - 70 PSQAEPASHKGPKDAGRRRNSLPPSHQKPPRNPLSSSDAAPSPELQANGTGTQGLEATDTNGLSSSARPQ 71 - 140 GQQAGSPSKEDKKQANIKRQLMTNFILGSFDDYSSDEDSVAGSSRESTRKGSRASLGALSLEAYLTTGEA 141 - 210 ETRVPTMRPSMSGLHLVKRGREHKKLDLHRDFTVASPAEFVTRFGGDRVIEKVLIANNGIAAVKCMRSIR 211 - 280 RWAYEMFRNERAIRFVVMVTPEDLKANAEYIKMADHYVPVPGGPNNNNYANVELIVDIAKRIPVQAVWAG 281 - 350 WGHASENPKLPELLCKNGVAFLGPPSEAMWALGDKIASTVVAQTLQVPTLPWSGSGLTVEWTEDDLQQGK 351 - 420 RISVPEDVYDKGCVKDVDEGLEAAERIGFPLMIKASEGGGGKGIRKAESAEDFPILFRQVQSEIPGSPIF 421 - 490 LMKLAQHARHLEVQILADQYGNAVSLFGRDCSIQRRHQKIVEEAPATIAPLAIFEFMEQCAIRLAKTVGY 491 - 560 VSAGTVEYLYSQDGSFHFLELNPRLQVEHPCTEMIADVNLPAAQLQIAMGVPLHRLKDIRLLYGESPWGV 561 - 630 TPISFETPSNPPLARGHVIAARITSENPDEGFKPSSGTVQELNFRSSKNVWGYFSVAATGGLHEFADSQF 631 - 700 GHCFSWGENREEAISNMVVALKELSIRGDFRTTVEYLINLLETESFQNNDIDTGWLDYLIAEKVQAEKPD 701 - 770 IMLGVVCGALNVADAMFRTCMTDFLHSLERGQVLPADSLLNLVDVELIYGGVKYILKVARQSLTMFVLIM 771 - 840 NGCHIEIDAHRLNDGGLLLSYNGNSYTTYMKEEVDSYRITIGNKTCVFEKENDPTVLRSPSAGKLTQYTV 841 - 910 EDGGHVEAGSSYAEMEVMKMIMTLNVQERGRVKYIKRPGAVLEAGCVVARLELDDPSKVHPAEPFTGELP 911 - 980 AQQTLPILGEKLHQVFHSVLENLTNVMSGFCLPEPVFSIKLKEWVQKLMMTLRHPSLPLLELQEIMTSVA 981 - 1050 GRIPAPVEKSVRRVMAQYASNITSVLCQFPSQQIATILDCHAATLQRKADREVFFINTQSIVQLVQRYRS 1051 - 1120 GIRGYMKTVVLDLLRRYLRVEHHFQQAHYDKCVINLREQFKPDMSQVLDCIFSHAQVAKKNQLVIMLIDE 1121 - 1190 LCGPDPSLSDELISILNELTQLSKSEHCKVALRARQILIASHLPSYELRHNQVESIFLSAIDMYGHQFCP 1191 - 1260 ENLKKLILSETTIFDVLPTFFYHANKVVCMASLEVYVRRGYIAYELNSLQHRQLPDGTCVVEFQFMLPSS 1261 - 1330 HPNRMTVPISITNPDLLRHSTELFMDSGFSPLCQRMGAMVAFRRFEDFTRNFDEVISCFANVPKDTPLFS 1331 - 1400 EARTSLYSEDDCKSLREEPIHILNVSIQCADHLEDEALVPILRTFVQSKKNILVDYGLRRITFLIAQEKE 1401 - 1470 FPKFFTFRARDEFAEDRIYRHLEPALAFQLELNRMRNFDLTAVPCANHKMHLYLGAAKVKEGVEVTDHRF 1471 - 1540 FIRAIIRHSDLITKEASFEYLQNEGERLLLEAMDELEVAFNNTSVRTDCNHIFLNFVPTVIMDPFKIEES 1541 - 1610 VRYMVMRYGSRLWKLRVLQAEVKINIRQTTTGSAVPIRLFITNESGYYLDISLYKEVTDSRSGNIMFHSF 1611 - 1680 GNKQGPQHGMLINTPYVTKDLLQAKRFQAQTLGTTYIYDFPEMFRQALFKLWGSPDKYPKDILTYTELVL 1681 - 1750 DSQGQLVEMNRLPGGNEVGMVAFKMRFKTQEYPEGRDVIVIGNDITFRIGSFGPGEDLLYLRASEMARAE 1751 - 1820 GIPKIYVAANSGARIGMAEEIKHMFHVAWVDPEDPHKGFKYLYLTPQDYTRISSLNSVHCKHIEEGGESR 1821 - 1890 YMITDIIGKDDGLGVENLRGSGMIAGESSLAYEEIVTISLVTCRAIGIGAYLVRLGQRVIQVENSHIILT 1891 - 1960 GASALNKVLGREVYTSNNQLGGVQIMHYNGVSHITVPDDFEGVYTILEWLSYMPKDNHSPVPIITPTDPI 1961 - 2030 DREIEFLPSRAPYDPRWMLAGRPHPTLKGTWQSGFFDHGSFKEIMAPWAQTVVTGRARLGGIPVGVIAVE 2031 - 2100 TRTVEVAVPADPANLDSEAKIIQQAGQVWFPDSAYKTAQAVKDFNREKLPLMIFANWRGFSGGMKDMYDQ 2101 - 2170 VLKFGAYIVDGLRQYKQPILIYIPPYAELRGGSWVVIDATINPLCIEMYADKESRGGVLEPEGTVEIKFR 2171 - 2240 KKDLIKSMRRIDPAYKKLMEQLGEPDLSDKDRKDLEGRLKAREDLLLPIYHQVAVQFADFHDTPGRMLEK 2241 - 2310 GVISDILEWKTARTFLYWRLRRLLLEDQVKQEILQASGELSHVHIQSMLRRWFVETEGAVKAYLWDNNQV 2311 - 2380 VVQWLEQHWQAGDGPRSTIRENITYLKHDSVLKTIRGLVEENPEVAVDCVIYLSQHISPAERAQVVHLLS 2381 - 2450 TMDSPAST 2451 - 2458 //
| PMID | Year | Title |
|---|---|---|
| 26030797 | 2015 | The ACACB gene rs2268388 polymorphism is associated with nephropathy in Caucasian patients with diabetes: a meta-analysis. |
| 26022126 | 2015 | Acetyl-CoA carboxylase 2 suppression rescues human proximal tubular cells from palmitic acid induced lipotoxicity via autophagy. |
| 25262148 | 2015 | The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis. |
| 24275569 | 2014 | An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. |
| 23460794 | 2013 | An ACACB variant implicated in diabetic nephropathy associates with body mass index and gene expression in obese subjects. |
| 23156397 | 2012 | [Genetic study for diabetic microvascular complications--recent advances and future perspectives]. |
| 23081748 | 2013 | ACAC? gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. |
| 21953464 | 2011 | Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion. |
| 21908218 | 2011 | Association of ACACB polymorphisms with obesity and diabetes. |
| 21887335 | 2011 | The effect of ACACB cis-variants on gene expression and metabolic traits. |
| More... |
